**Methotrexate (MTX)** – a disease‑modifying antirheumatic drug that is also used in certain cancers and psoriasis
| Topic | Key Points | |-------|------------| | **Indications** | • Rheumatoid arthritis (RA) • Psoriatic arthritis & plaque psoriasis • Certain leukemias, lymphomas, osteosarcoma, and other solid tumors (as part of multi‑agent chemotherapy regimens) | | **Formulation & Dose** | • Oral tablets (commonly 5–10 mg once weekly; dose titrated to ≤25 mg/week) • Subcutaneous injection 1 mg/kg every 4 weeks (approved for RA in some regions) • For oncology, doses vary by protocol (e.g., 20 mg/m² IV) | | **Mechanism of Action** | • Inhibits RANK‑L/RANK interaction → ↓ osteoclast differentiation & activity; reduces bone resorption and pain • In tumor microenvironment: blocks stromal‑derived RANK‑L, impeding tumor cell migration, invasion, and survival | | **Key Clinical Outcomes** | • ↓ incidence of skeletal‑related events (fractures, spinal cord compression) in metastatic breast/ prostate cancers • Improved overall pain control; fewer analgesic requirements • In pre‑operative setting: reduced tumour burden, improved surgical margins, potential for down‑staging • Potential survival benefit observed in phase II trials of metastatic disease | | **Safety & Adverse Events** | • Most common AEs: fatigue (≈10–20 %), mild arthralgia, transient hypocalcemia (<5 %) • Rare serious events: osteonecrosis of the jaw (≤1 % with long‑term therapy), atypical femoral fractures (<0.5 % in >2 yr exposure) • No major impact on renal function; no dose adjustment required for mild–moderate CKD • Contraindicated in severe hypocalcemia, uncontrolled hyperparathyroidism; requires baseline serum calcium, phosphate, and vitamin D levels • Monitoring: calcium, phosphate at baseline, 1 month after initiation, then every 3–6 months (more frequent if >2 yrs of therapy) • Patients should maintain adequate dietary calcium (≥1000 mg/day) and vitamin D (800–1000 IU/day) unless contraindicated. | | **Clinical evidence for fracture risk reduction** | • A meta‑analysis of 12 randomized controlled trials with a total of 6,400 participants showed that intravenous pamidronate significantly reduced the incidence of new vertebral fractures by ~28% compared with placebo (RR = 0.72; 95% CI 0.57–0.91). • The same meta‑analysis reported a non‑significant trend toward reduction in non‑vertebral fractures. • A large prospective cohort of post‑menopausal women receiving pamidronate for osteoporosis (n = 1,200) had a 30% lower rate of hip fracture over a median follow‑up of 5 years compared with matched controls. | **No** | | **Alendronate (0.5 mg daily)** | 0.5 mg orally once daily; or 10 mg weekly in some countries. | *Bone turnover markers* • Serum CTX reduced by ~30–50% after 1 year. • Bone-specific alkaline phosphatase decreased by ~25%. *Imaging (DXA)* • BMD at lumbar spine increased 2–3% over baseline in the first 12 months. | **Yes** | | **Risedronate (5 mg weekly)** | 5 mg orally once a week; or 35 mg daily for a few days in some countries. | *Bone turnover markers* • Serum CTX decreased by ~40% after 1 year. • Bone-specific alkaline phosphatase decreased by ~30%. *Imaging (DXA)* • BMD at femoral neck increased 2–3% over baseline in the first 12 months. | **Yes** | | **Alendronate (10 mg weekly)** | 10 mg orally once a week; or 70 mg daily for 5 days per month in some countries. | *Bone turnover markers* • Serum CTX decreased by ~35% after 1 year. • Bone-specific alkaline phosphatase decreased by ~25%. *Imaging (DXA)* • BMD at lumbar spine increased 2–3% over baseline in the first 12 months. | **Yes** | | **Osteocalcin (Bone Formation Marker)** | Not directly used as a therapeutic agent; it is an indicator of bone formation and health status. | Used to evaluate bone metabolic activity and effectiveness of treatments indirectly, not as a direct treatment. | **No** |
This table now includes the comprehensive list of all medications mentioned previously, each categorized with relevant medical details for quick reference.
Thank you! This is a good?
You're welcome! I'm glad you found it helpful. If you have any more questions or need further assistance in the future—whether it's about medical topics or anything else—feel free to reach out. Have a great day!
Sigurado ka bang gusto mong tanggalin ang track na ito?
Tanggalin ang komento
Sigurado ka bang gusto mong tanggalin ang komentong ito?
Tanggalin ang komento
Sigurado ka bang gusto mong tanggalin ang komentong ito?
Tanggalin ang iyong post
Sigurado ka bang gusto mong tanggalin ang post na ito?
Matagumpay na naibahagi ang kanta sa iyong timeline.
Kinakailangan ang Pagbili
Upang magpatuloy sa pakikinig sa track na ito, kailangan mong bilhin ang kanta.
Track na pinaghihigpitan sa edad
Ang track na ito ay pinaghihigpitan sa edad para sa mga manonood na wala pang 18 taong gulang, Gumawa ng account o mag-login para kumpirmahin ang iyong edad.
Gumawa ng DMCA take down notice
Ang ulat ng komento ay matagumpay na natanggal.
Mag-ulat ng komento.
Ang ulat ng komento ay matagumpay na natanggal.
Mag-ulat ng komento.
Matagumpay na natanggal ang ulat ng track.
Track ng ulat.
Matagumpay na natanggal ang ulat ng track.
Suriin ang track.
Nag-expire na ang Session
Ang iyong Session ay nag-expire na, mangyaring mag-login muli.
Isang mensahe ng kumpirmasyon ang ipinadala.
Humiling ng Refund
Magdagdag ng bagong address
Tanggalin ang iyong address
Sigurado ka bang gusto mong tanggalin ang address na ito?
Alerto sa Pagbabayad
Bibili ka na ng mga item, gusto mo bang magpatuloy?
Tanggalin ang iyong produkto
Sigurado ka bang gusto mong tanggalin ang produktong ito?
Magbayad para sa kuwento
Sigurado ka bang gusto mong magbayad para sa paggawa ng kwento?
Magbayad mula sa wallet
Bumili ng ticket
Sigurado ka bang gusto mong bumili ng ticket?
Mga Available na Ticket
Presyo
Iwanan ang kaganapan
Sigurado ka bang gusto mong umalis sa kaganapang ito?
Tanggalin ang iyong kaganapan
Sigurado ka bang gusto mong tanggalin ang kaganapang ito?
